Different doses and courses of omalizumab for patients with chronic spontaneous urticaria: A systematic review with meta-analysis and trial sequential analysis
Background: The stability, efficacy, and safety of omalizumab at different doses and regimens for chronic spontaneous urticaria (CSU) are yet to be studied. Objective: A systematic review (SR) with meta-analysis (MA) and trial sequential analysis (TSA) was performed to assess the efficacy and safety...
Main Authors: | Haiyan Qin, MD, Xianjun Xiao, MD, PhD, Di Qin, MD, Peiwen Xue, MD, Huilin Liu, MD, Ying Li, MD, PhD, Yunzhou Shi, MD, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | World Allergy Organization Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455124000292 |
Similar Items
-
Retrospective analysis of the treatment of 61 cases of chronic spontaneous urticaria with omalizumab
by: Shanshan OU, et al.
Published: (2023-04-01) -
Mapping the intellectual structure of the research of omalizumab in chronic spontaneous urticaria: A bibliometric analysis
by: Yuxu Yao, MD, et al.
Published: (2024-05-01) -
Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China
by: Ao Wang, MD, et al.
Published: (2022-12-01) -
Expert consensus on the use of omalizumab in chronic urticaria in China
by: Zuotao Zhao, MD, PhD, et al.
Published: (2021-11-01) -
Type I and type IIb autoimmune chronic spontaneous urticaria: Using common clinical tools for endotyping patients with CSU
by: Juliana A. Sella, MD, PhD, et al.
Published: (2023-11-01)